Search companies or stocks...
Coherus Oncology, Inc. (CHRS) current market price $1.42; calculated gap vs modeled fair value is 732.50%. The dollar intrinsic value estimate is available with Tickerplace Pro.
Confidence score is based on the magnitude of the gap vs the modeled estimate.
Fair value estimate
Unlock fair valueCurrent price
$1.42
Intrinsic value work for Coherus Oncology, Inc. anchors fair value on owner earnings and balance-sheet capacity, then places the current quote next to that estimate.
Versus historical valuation bands, CHRS can sit toward the lower or upper end of where this business has traded when profitability and growth were comparable — useful context before reading any single headline multiple.
Sector peers and macro rates still deserve a sanity check on the company page. The percentage gap on this snapshot is a model output, not a recommendation.
Coherus Oncology, Inc. (CHRS) current market price is $1.42, a calculated difference of 732.5% versus modeled fair value. Tickerplace Pro unlocks the dollar intrinsic value estimate. This is a model output, not a recommendation.
Intrinsic value is an estimate of what CHRS shares may be worth based on fundamentals rather than today's price alone. See the valuation snapshot on this page for the latest model output. Tickerplace Pro unlocks the full dollar fair value estimate.
Tickerplace calculates CHRS's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to show the calculated gap.
CHRS’s calculated gap versus modeled fair value is 732.5% at a market price of $1.42. A gap is a calculated difference between price and the model estimate, not a buy or sell conclusion. Confirm with ratios and financials on the company profile.
Peers for CHRS: open their calculated fair value vs price view.
